SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Valentine Karen

(Last)

(First)

(Middle)

C/O ANTIGENICS INC.

3 FORBES RD

(Street)

LEXINGTON

02421

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2008

3. Issuer Name and Ticker or Trading Symbol
ANTIGENICS INC /DE/ [ agen ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP and General Counsel

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,106	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option, right to buy	03/22/2005⁽¹⁾	03/22/2014	Common Stock	15,000	$10.17	D
Stock Option, right to buy	03/07/2006⁽²⁾	03/07/2015	Common Stock	7,500	$6.3	D
Stock Option, right to buy	01/01/2007⁽³⁾	01/01/2016	Common Stock	7,500	$4.76	D
Stock Option, right to buy	03/22/2007⁽⁴⁾	03/22/2016	Common Stock	7,500	$5.13	D
Stock Option, right to buy	09/15/2007⁽⁵⁾	09/15/2016	Common Stock	12,500	$1.63	D
Stock Option, right to buy	12/04/2007⁽⁶⁾	12/04/2016	Common Stock	30,000	$2.03	D
Restricted Stock	01/05/2009⁽⁷⁾	01/05/2017	Common Stock	5,209	$0	D
Stock Option, right to buy	09/12/2008⁽⁸⁾	09/12/2017	Common Stock	48,900	$2.27	D
Restricted Stock	07/10/2008⁽⁹⁾	01/10/2018	Common Stock	16,376	$0	D
Restricted Stock	01/10/2009⁽¹⁰⁾	01/10/2018	Common Stock	16,375	$0	D

Explanation of Responses:

1. Options vest in four equal annual installments beginning March 22, 2005.

2. Options vest in four equal annual installments beginning March 7, 2006.

3. Options vest in four equal annual installments beginning January 1, 2007.

4. Options vest in three equal annual installments beginning March 22, 2007.

5. Options vest 33% on September 15, 2007 and 67% on September 15, 2008.

6. Options vest in four equal annual installments beginning December 4, 2007.

7. Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 5, 2009.

8. Options vest in four equal annual installments beginning September 12, 2008.

9. Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended and vests on July 10, 2008.

10. Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests on January 10, 2009.

	Christine M. Klaskin, by Power of Attorney	06/09/2008
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.